FLEMINGTON, N.J., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that David Jackson, Ph.D., Vice President of Diagnostics & Companion Diagnostics, has been selected to present at the 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference, being held October 27-29, 2014 in Alexandria, Va.
"The biotechnology and diagnostic industries face unique challenges to optimally develop, secure regulatory approval for and co-commercialize new cancer therapies and companion diagnostics in a timely manner," commented Dr. Jackson. "It is a privilege to have the opportunity to discuss these barriers as well as commercial considerations, perspectives and solutions to overcome them at this innovative conference. The Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference continues to provide an open-dialogue forum for regulators, industry and key opinion leaders to discuss fresh and successful approaches to navigate the evolving regulatory environment."
Dr. Jackson is responsible for managing Arno's companion diagnostic program. Arno has partnered with Leica Biosystems Ltd (Newcastle UK) to manufacture the companion diagnostic kit to support the development and global registration of the Company's lead compound onapristone, a targeted oncology therapeutic directed at the activated progesterone receptor. In addition, Arno has engaged Clarient Diagnostic Services, Inc. (a GE Healthcare Company) to perform diagnostic laboratory services for the clinical development of onapristone.
Dr. Jackson will present during the one-day workshop titled, "Clinical & Regulatory Strategies for Companion Diagnostics," taking place on Wednesday, October 29. In the presentation, entitled, "Commercial Considerations in Companion Diagnostic Partnerships: Development to Launch," Dr. Jackson will discuss proactive strategies, tactics and solutions for co-commercialization partnerships between pharmaceutical and diagnostic development companies to ensure commercial pathways are well-aligned.
Details of Dr. Jackson's presentations are as follows:
|Conference:||5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference|
|Title:||Commercial Considerations in Companion Diagnostic Partnerships: Development to Launch|
|Day:||Wednesday, October 29, 2014|
|Time:||9:20 a.m. EDT|
Onapristone is an oral, anti-progestin hormone blocker that has been shown in previous Phase II clinical trials (not sponsored by Arno) to exhibit anti-tumor activity in patients with breast cancer. In pre-clinical testing, onapristone has been shown to block the activation of the progesterone receptor (PR), which is believed to be a mechanism that inhibits the growth of activated progesterone receptor (APR) driven breast, endometrial and other, primarily gynecological tumors. APR has the potential to function as a biomarker of anti-progestin activity, as detected by a companion diagnostic currently under development.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit www.arnothera.com.
CONTACT: The Ruth Group Lee Roth (investors) firstname.lastname@example.org (646) 536-7012 Kirsten Thomas (media) email@example.com (646) 536-7014 Arno Therapeutics Lawrence Kenyon firstname.lastname@example.org (862) 703-7171
Source:Arno Therapeutics Inc.